Date |
Company |
Amount |
Funding type |
Investors |
Therapeutic area |
Type of Information |
2016-08-08 |
Fate Therapeutics (USA - CA) |
$10.3 million |
private placement |
|
Cancer - Oncology - Immunological diseases |
Private placement |
2016-08-02 |
Avrobio (USA - MA) |
$25 million |
series A financing round |
Atlas Venture (USA) Clarus (USA) SV Life Sciences (USA) |
Cancer - Oncology - Rare diseases - Genetic diseases |
Series A financing round |
2016-07-31 |
InflaRX (Germany), international industrial investors, family offices, existing investors. |
€ 31 million ($ 34 million) |
series C financing round |
Staidson Hongkong Investment Company (China) |
Inflammatory diseases |
Series C financing round |
2016-07-29 |
Biophytis (France) |
€ 1.1 million |
loan |
Bpifrance (France) |
Muscle disorders |
Loan |
2016-07-28 |
Nicox (France) |
€18 million |
capital increase |
|
Ophtalmological diseases |
Capital increase |
2016-07-19 |
Precision Ocular (UK) |
£15.5 million |
series A financing round |
Imperial Innovations (UK) Consort Medical (UK) NeoMed (Switzerland) V?Bio Ventures (Belgium) Hovione Scientia (Portugal) |
Ophtalmological diseases |
Series A financing round |
2016-07-19 |
Auris Medical (Switzerland) |
up to $ 20 million |
loan |
Hercules Capital (USA - CA) |
Otorhinolaryngology |
Loan |
2016-07-18 |
Poxel (France) |
€26.5 million |
capital increase |
institutional investors in the United States and in Europe. |
Metabolic diseases |
Capital increase |
2016-07-13 |
Galena Biopharma (USA - OR) |
$11.7 million |
private placement |
|
Cancer - Oncology |
Private placement |
2016-07-08 |
Horama (France) |
fundraising |
€ 4 million |
Bpifrance (France) and private investors (shareholders and Vendée entrepreneurs) Omnes Capital (France) Go Capital (France) Sham Innovation (France) |
Ophtalmological diseases |
Series A financing round |
2016-06-30 |
Bionor Pharma (Norway) |
|
private placement |
|
Infectious diseases |
Private placement |
2016-06-29 |
Paion (Germany) |
€ 9.6 million |
capital increase |
Cosmo Pharmaceuticals (Ireland) Granell Strategic Investment Fund (ireland) |
CNS diseases |
Capital increase |
2016-06-27 |
Emergent Biosolutions (USA - MD) |
up to $21.9 million |
grant |
Biomedical Advanced Research and Development Authority (BARDA) (USA) |
Infectious diseases |
Grant |
2016-06-24 |
Global Blood Therapeutics (USA - CA) |
$112.3 million |
private placement |
|
Rare diseases - Genetic diseases - Hematological diseases |
Private placement |
2016-06-22 |
Neovacs (France) |
€ 8.7 million |
capital increase |
|
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
Capital increase |
2016-06-20 |
F2G (UK) |
$60 million (€ 52.8 milion) |
financing round |
Sectoral Asset Management (Canada) Novo A/S (Denmark) Aisling Capital (USA - NY) Brace Pharma Capital (USA - MD) Advent Life Sciences (UK) Novartis Venture Fund (Switzerland) Sunstone Capital (Denmark) Merifin Capital (UK) |
Infectious diseases |
Financing round |
2016-06-20 |
Spark Therapeutics (USA - PA) |
$128.0 million |
private placement |
|
Rare diseases - Genetic diseases |
Private placement |
2016-06-15 |
Allecra Therapeutics (Germany - France) |
€22 million |
series B financing round |
Delos Capital (USA - NY) Forbion Capital Partners (The Netherlands) Edmond de Rothschild Investment Partners (France) EMBL Ventures (Germany) Nicholas Benedict |
Infectious diseases |
Series B financing round |
2016-06-15 |
Corbus Pharmaceuticals (USA - MA) |
$15 million |
private placement |
|
Fibrotic diseases - Inflammatory diseases |
Private placement |
2016-06-09 |
Mereo BioPharma (UK) |
£14.8 million |
IPO |
|
Rare diseases |
IPO |